| Code | 5109D | ||||||||||
| MA number | 14/0165/20-S | ||||||||||
| Product Form: | sus inh 1x60 dávok (inh.Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | AstraZeneca AB, Sweden | ||||||||||
| Therapeutic Class: | 14 - BRONCHODILATANTIA, ANTIASTHMATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 24 | ||||||||||
| Container: | inhaler Al | ||||||||||
| Route of admin.: | Inhalation use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10b fixed combination application |
| MA issued: | 31.07.2020 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Symbicort 80 mcg_2,25 mcg_04.2021.pdf
|
| PIL: |
PIL_Symbicort 80 mikrogramov/2,25 mikrogramov_11/2024.pdf
|
| Safety feature | Yes |
| Data update: | 17.12.2024 |
